Phase II trial of trimelamol in refractory ovarian cancer.

Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using t...

Descripción completa

Detalles Bibliográficos
Autores principales: Judson, I. R., Calvert, A. H., Gore, M. E., Balmanno, K., Gumbrell, L. A., Perren, T., Wiltshaw, E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971798/
https://www.ncbi.nlm.nih.gov/pubmed/1997112
_version_ 1782134987568447488
author Judson, I. R.
Calvert, A. H.
Gore, M. E.
Balmanno, K.
Gumbrell, L. A.
Perren, T.
Wiltshaw, E.
author_facet Judson, I. R.
Calvert, A. H.
Gore, M. E.
Balmanno, K.
Gumbrell, L. A.
Perren, T.
Wiltshaw, E.
author_sort Judson, I. R.
collection PubMed
description Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.
format Text
id pubmed-1971798
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19717982009-09-10 Phase II trial of trimelamol in refractory ovarian cancer. Judson, I. R. Calvert, A. H. Gore, M. E. Balmanno, K. Gumbrell, L. A. Perren, T. Wiltshaw, E. Br J Cancer Research Article Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease. Nature Publishing Group 1991-02 /pmc/articles/PMC1971798/ /pubmed/1997112 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Judson, I. R.
Calvert, A. H.
Gore, M. E.
Balmanno, K.
Gumbrell, L. A.
Perren, T.
Wiltshaw, E.
Phase II trial of trimelamol in refractory ovarian cancer.
title Phase II trial of trimelamol in refractory ovarian cancer.
title_full Phase II trial of trimelamol in refractory ovarian cancer.
title_fullStr Phase II trial of trimelamol in refractory ovarian cancer.
title_full_unstemmed Phase II trial of trimelamol in refractory ovarian cancer.
title_short Phase II trial of trimelamol in refractory ovarian cancer.
title_sort phase ii trial of trimelamol in refractory ovarian cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971798/
https://www.ncbi.nlm.nih.gov/pubmed/1997112
work_keys_str_mv AT judsonir phaseiitrialoftrimelamolinrefractoryovariancancer
AT calvertah phaseiitrialoftrimelamolinrefractoryovariancancer
AT goreme phaseiitrialoftrimelamolinrefractoryovariancancer
AT balmannok phaseiitrialoftrimelamolinrefractoryovariancancer
AT gumbrellla phaseiitrialoftrimelamolinrefractoryovariancancer
AT perrent phaseiitrialoftrimelamolinrefractoryovariancancer
AT wiltshawe phaseiitrialoftrimelamolinrefractoryovariancancer

Ejemplares similares